NantOmics provided the funding for Genos as it gets ready to commercially launch its exome sequencing service.
NantOmics, a cancer care development branch of healthcare technology developer NantWorks, has invested $6m in US-based genome sequencing technology startup Genos, TechCrunch has reported.
Genos will provide a service that sequences a user’s exome, the part of the human genome that encodes genes, through a saliva sample in order to provide information on possible tendencies toward certain diseases.
Founded in May this year, Genos is currently preparing to commercially launch its testing kit.
– Image courtesy of Genos Research, Inc.
